Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both revenue and profitability. Management pointed to the successful launch of the Highmark contract and robust customer renewals as key drivers. CEO Seth Blackley specifically highlighted that clinical engagement metrics for new partnerships, such as Aetna and Highmark, were trending above target, signaling strong execution in the company’s core value-based care solutions. Evolent’s ongoing focus on automation, particularly through its Auth Intelligence platform, was also cited as a contributor to operational efficiency.
Is now the time to buy EVH? Find out in our full research report (it’s free for active Edge members).
Evolent Health (EVH) Q2 CY2026 Highlights:
- Revenue: $652.5 million vs analyst estimates of $596.7 million (46.9% year-on-year growth, 9.4% beat)
- Adjusted EPS: $0.02 vs analyst estimates of -$0.02 (significant beat)
- Adjusted EBITDA: $28.05 million vs analyst estimates of $23.14 million (4.3% margin, 21.2% beat)
- The company lifted its revenue guidance for the full year to $2.65 billion at the midpoint from $2.5 billion, a 6% increase
- EBITDA guidance for the full year is $127.5 million at the midpoint, in line with analyst expectations
- Operating Margin: -1.5%, down from -0.3% in the same quarter last year
- Sales Volumes were down 1.8% year on year
- Market Capitalization: $471.5 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Evolent Health’s Q2 Earnings Call
-
Kevin Caliendo (UBS) asked about Evolent’s reserving process in light of industry utilization trends, and CFO Mario Ramos stated the company’s approach aligns with broader industry practices and he feels “comfortably optimistic” about their adequacy.
-
John Stansel (JPMorgan) inquired whether margin compression is expected as new Performance Suite contracts scale. Ramos explained that while overall margins appear lower due to contract mix, margins within the Performance Suite itself are improving as contracts mature.
-
Zachary Haggerty (KeyBanc Capital Markets) questioned trends in oncology cost structure, and CEO Seth Blackley confirmed drugs remain roughly 75% of oncology costs, with little change in the overall cost mix.
-
Eduardo Ron (Truist) sought quantification of Medicaid and exchange headwinds versus Medicare Advantage growth. Ramos estimated a 20% decline in Medicaid expansion members but emphasized that Performance Suite contract wins provide a meaningful offset.
-
Luismario Higuera (Citi) asked about the current size of the new business pipeline; Blackley reported that the pipeline has refilled, with several large national plans now under consideration, particularly in oncology.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team is closely monitoring (1) the pace and quality of major Performance Suite launches, especially in oncology and with new large clients; (2) the operational impact and financial returns from scaling the Auth Intelligence platform across client contracts; and (3) the company’s ability to mitigate membership attrition in Medicaid and exchanges through cross-selling and new client wins. Progress on cost reduction and further customer renewals will also be critical markers for sustained growth.
Evolent Health currently trades at $4.15, up from $3.08 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
